Pharmicell (005690.KS)
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; Hearticellgram_AMI, a cardiac disease drug; Cellgram_CKD for the treatment of chronic kidney disease; and Cellgram_AKI for the treatment of acute kidney disease. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, as well as clinical development and commercialization services for new drugs. Further, it operates Twelve, a stem cell bank; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Company Info
Highlights
₩796.25B
₩63.10B
₩25.84B
₩4,289.25 - ₩14,200.00
₩17,500.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of ₩10,000 in Pharmicell, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading data...
Returns By Period
Pharmicell (005690.KS) has returned 60.27% so far this year and 150.06% over the past 12 months. Over the last ten years, 005690.KS has returned 9.83% per year, falling short of the S&P 500 benchmark, which averaged 11.51% annually.
005690.KS
- YTD
- 60.27%
- 1M
- 19.12%
- 6M
- 57.23%
- 1Y
- 150.06%
- 3Y*
- 1.43%
- 5Y*
- -8.33%
- 10Y*
- 9.83%
^GSPC (Benchmark)
- YTD
- 7.06%
- 1M
- 5.28%
- 6M
- 5.00%
- 1Y
- 14.38%
- 3Y*
- 16.95%
- 5Y*
- 14.32%
- 10Y*
- 11.51%
Monthly Returns
The table below presents the monthly returns of 005690.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Based on daily data since Dec 1995, the average daily return (also called the expected return) is 0.14%, while the average monthly return is 3.14%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -3.62% | 26.57% | 0.40% | 4.04% | 11.28% | 13.12% | -7.23% | 48.79% | |||||
| 2024 | -5.93% | -5.43% | 15.74% | -5.76% | 1.36% | -6.20% | -6.43% | 11.64% | -7.52% | -6.28% | -6.61% | 75.31% | 36.75% |
| 2023 | -7.88% | -7.20% | -5.49% | -0.66% | -2.21% | -16.01% | -8.46% | 1.91% | 3.88% | -14.40% | -2.59% | 0.83% | -46.28% |
| 2022 | -21.84% | 7.35% | 3.65% | 0.88% | 36.24% | -26.28% | 0.00% | 9.13% | -17.93% | -0.97% | -0.49% | 11.33% | -13.41% |
| 2021 | -16.76% | 11.46% | -6.23% | 9.97% | 2.72% | 6.76% | -7.71% | -2.39% | -9.17% | -16.16% | 5.22% | -0.38% | -24.57% |
| 2020 | -7.89% | -1.02% | 166.15% | -7.77% | 26.84% | -23.65% | 23.10% | -1.10% | -19.42% | -2.49% | 16.19% | -15.40% | 103.77% |
| 2019 | 45.08% | -31.64% | -2.48% | -4.24% | -19.29% | -14.69% | 6.94% | -9.62% | -5.45% | 21.24% | -11.02% | 10.69% | -30.41% |
| 2018 | 7.19% | -0.16% | 157.38% | 10.19% | 13.58% | -19.34% | -16.40% | 36.60% | -8.56% | -27.19% | 14.11% | -11.27% | 114.04% |
| 2017 | -8.19% | 3.67% | -7.09% | -5.12% | -4.48% | 1.44% | -8.06% | 2.32% | -1.39% | 7.28% | 16.79% | 16.21% | 9.83% |
| 2016 | 9.85% | 14.69% | -4.33% | 10.63% | 19.75% | -4.61% | 0.62% | -16.87% | 4.47% | -17.83% | 1.30% | 11.13% | 23.13% |
| 2015 | -3.04% | 18.84% | 5.42% | 2.88% | 1.58% | 8.39% | 42.26% | -17.73% | -5.48% | -1.90% | -9.48% | -5.07% | 28.31% |
| 2014 | -3.97% | 8.68% | -2.92% | 3.13% | -11.14% | -0.57% | -15.19% | -0.34% | 51.53% | 7.16% | -14.09% | -20.17% | -13.10% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 90, 005690.KS is among the top 10% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Pharmicell (005690.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Pharmicell provided a 0.16% dividend yield over the last twelve months, with an annual payout of ₩20.00 per share.
| Period | TTM | 2024 |
|---|---|---|
| Dividend | ₩20.00 | ₩20.00 |
Dividend yield | 0.16% | 0.24% |
Monthly Dividends
The table displays the monthly dividend distributions for Pharmicell. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |||||
| 2024 | ₩20.00 | ₩20.00 |
Dividend Yield & Payout
Dividend Yield
Pharmicell has a dividend yield of 0.15%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
Pharmicell has a payout ratio of 7.43%, which is below the market average. This means Pharmicell returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Pharmicell. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Pharmicell was 97.13%, occurring on Aug 18, 1998. Recovery took 2664 trading sessions.
The current Pharmicell drawdown is 47.10%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.13% | May 16, 1996 | 552 | Aug 18, 1998 | 2664 | Jul 9, 2009 | 3216 |
| -82.9% | Apr 11, 2018 | 1556 | Aug 5, 2024 | — | — | — |
| -82.51% | Aug 19, 2009 | 74 | Dec 1, 2009 | 392 | Jun 29, 2011 | 466 |
| -80.43% | Jul 25, 2011 | 749 | Aug 20, 2014 | 878 | Mar 21, 2018 | 1627 |
| -21.4% | Dec 5, 1995 | 19 | Jan 5, 1996 | 16 | Jan 29, 1996 | 35 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Pharmicell over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Pharmicell, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how Pharmicell is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 005690.KS compared to other companies in the Biotechnology industry. 005690.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 005690.KS relative to other companies in the Biotechnology industry. Currently, 005690.KS has a P/S ratio of 33.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 005690.KS in comparison with other companies in the Biotechnology industry. Currently, 005690.KS has a P/B value of 8.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |